Stephen Huang
executive director Avenzo Therapeutics
Stephen Huang, is Executive Director of Clinical Biomarkers and Companion Diagnostics at Avenzo Therapeutics, where he leads biomarker strategy and precision medicine approaches to support oncology drug development, including emerging bispecific ADC programs.
He brings extensive experience in translational science and biomarker development across leading biotech and pharmaceutical companies, including roles at Artiva Biotherapeutics, Turning Point Therapeutics, AbbVie, Pfizer, and Exelixis.
With deep expertise in oncology and companion diagnostics, Stephen focuses on enabling data driven development and optimizing patient selection to advance next generation targeted therapies.
Seminars
Tuesday 13th October 2026
From Biology to the Clinic: Optimizing Rationale, Development & Translation of Bispecific ADCs
2:00 pm
- Breaking down biology rationale for pursuing bispecific ADC development and selecting target pairings
- Evaluating preclinical profiles of bispecific ADCs highlighting favorable efficacy and tolerability profiles against monospecific therapies
- Laying out considerations and strategy to optimize successful translational through biomarker and clinical development strategies
